Elevated CXCR3 expression in primary T-ALL samples compared with normal thymic cells further strengthens its therapeutic potential, and strategies targeting CXCR3 have already been explored in several cancers and inflammatory diseases (58, 79–82). This evidence concerns the gene CXCR3 and acute lymphoblastic leukemia.